Across TCGA pan-cancer cohorts, GM2A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GM2A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GM2A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GM2A is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where GM2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GM2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−2.013	<.001	12	view →
COAD	Female	III,IV	−0.564	<.001	7	view →
HNSC	Male	II,III,IV	+0.332	<.001	6	view →
LUAD	Male	All	−0.192	.034	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GM2A RNA expression & survival · all GM2A data types